the following reaction schemes illustrate the preparation of the compounds of the present invention . unless otherwise indicated r 2 , r 3 , r 4 and r 5 in the reaction schemes and the discussion that follow are defined as above . in reaction 1 of preparation a , the 4 - chloropyrrolo [ 2 , 3 - d ] pyrimidine compound of formula xxi , wherein r is hydrogen or a protecting group such as benzenesulfonyl or benzyl , is converted to the 4 - chloro - 5 - halopyrrolo [ 2 , 3 - d ] pyrimidine compound of formula xx , wherein y is chloro , bromo or iodo , by reacting xxi with n - chlorosuccinimide , n - bromosuccinimide or n - iodosuccinimide . the reaction mixture is heated to reflux , in chloroform , for a time period between about 1 hour to about 3 hours , preferably about 1 hour . alternatively , in reaction 1 of preparation a , the 4 - chloropyrrolo [ 2 , 3 - d ] pyrimidine of formula xxi , wherein r is hydrogen , is converted to the corresponding 4 - chloro - 5 - nitropyrrolo [ 2 , 3 - d ] pyrimidine of formula xx , wherein y is nitro , by reacting xxi with nitric acid in sulfuric acid at a temperature between about − 10 ° c . to about 10 ° c ., preferably about 0 ° c ., for a time period between about 5 minutes to about 15 minutes , preferably about 10 minutes . the compound of formula xxi , wherein y is nitro , is converted to the corresponding 4 - chloro - 5 - aminopyrrolo [ 2 , 3 - d ] pyrimidine of the formula xx , wherein y is amino , by reacting xxi under a variety of conditions known to one skilled in the art such as palladium hydrogenolysis or tin ( iv ) chloride and hydrochloric acid . in reaction 2 of preparation a , the 4 - chloro - 5 - halopyrrolo [ 2 , 3 - d ] pyrimidine compound of formula xx , wherein r is hydrogen , is converted to the corresponding compound of formula xix , wherein r 2 is ( c 1 - c 6 ) alkyl or benzyl , by treating xx with n - butyllithium , at a temperature of about − 78 ° c ., and reacting the dianion intermediate so formed with an alkylhalide or benzylhalide at a temperature between about − 78 ° c . to room temperature , preferably room temperature . alternatively , the dianion so formed is reacted with molecular oxygen to form the corresponding 4 - chloro - 5 - hydroxypyrrolo [ 2 , 3 - d ] pyrimidine compound of formula xix , wherein r 2 is hydroxy . the compound of formula xx , wherein y is bromine or iodine and r is benzenesulfonate , is converted to the compound of formula xix , wherein r 2 is ( c 6 - c 12 ) aryl or vinyl , by treating xx with n - butyllithium , at a temperature of about − 78 ° c ., followed by the addition of zinc chloride , at a temperature of about − 78 ° c . the corresponding organo zinc intermediate so formed is then reacted with aryliodide or vinyl iodide in the presence of a catalytic quantity of palladium . the reaction mixture is stirred at a temperature between about 50 ° c . to about 80 ° c ., preferably about 70 ° c ., for a time period between about 1 hour to about 3 hours , preferably about 1 hour . in reaction 3 of preparation a , the compound of formula xix is converted to the corresponding compound of formula xvi by treating xix with n - butyllithium , lithium diisopropylamine or sodium hydride , at a temperature of about − 78 ° c ., in the presence of a polar aprotic solvent , such as tetrahydrofuran . the anionic intermediate so formed is further reacted with ( a ) alkylhalide or benzylhalide , at a temperature between about − 78 ° c . to room temperature , preferably − 78 ° c ., when r 3 is alkyl or benzyl ; ( b ) an aldehyde or ketone , at a temperature between about − 78 ° c . to room temperature , preferably − 78 ° c ., when r 3 is alkoxy ; and ( c ) zinc chloride , at a temperature between about − 78 ° c . to room temperature , preferably − 78 ° c ., and the corresponding organozinc intermediate so formed is then reacted with aryliodide or vinyl iodide in the presence of a catalytic quantity of palladium . the resulting reaction mixture is stirred at a temperature between about 50 ° c . to about 80 ° c ., preferably about 70 ° c ., for a time period between about 1 hour to about 3 hours , preferably about 1 hour . alternatively , the anion so formed is reacted with molecular oxygen to form the corresponding 4 - chloro - 6 - hydroxypyrrolo [ 2 , 3 - d ] pyrimidine compound of formula xvi , wherein r 3 is hydroxy . in reaction 1 of preparation b , the 4 - chloropyrrolo [ 2 , 3 - d ] pyrimidine compound of formula xxi is converted to the corresponding compound of formula xxii , according to the procedure described above in reaction 3 of preparation a . in reaction 2 of preparation b , the compound of formula xxii is converted to the corresponding compound of formula xvi , according to the procedures described above in reactions 1 and 2 of preparation a . in reaction 1 of scheme 1 , the 4 - chloropyrrolo [ 2 , 3 - d ] pyrimidine compound of formula xvii is converted to the corresponding compound of formula xvi , wherein r is benzenesulfonyl or benzyl , by treating xvii with benzenesulfonyl chloride , benzylchloride or benzylbromide in the presence of a base , such as sodium hydride or potassium carbonate , and a polar aprotic solvent , such as dimethylformamide or tetrahydrofuran . the reaction mixture is stirred at a temperature between about 0 ° c . to about 70 ° c ., preferably about 30 ° c ., for a time period between about 1 hour to about 3 hours , preferably about 2 hours . in reaction 2 of scheme 1 , the 4 - chloropyrrolo [ 2 , 3 - d ] pyrimidine compound of formula xvi is converted to the corresponding 4 - aminopyrrolo [ 2 , 3 - d ] pyrimidine compound of formula xv by coupling xvi with an amine of the formula hnr 4 r 5 . the reaction is carried out in an alcohol solvent , such as tert - butanol , methanol or ethanol , or other high boiling organic solvents , such as dimethylformamide , triethylamine , 1 , 4 - dioxane or 1 , 2 - dichloroethane , at a temperature between about 60 ° c . to about 120 ° c ., preferably about 80 ° c . typical reaction times are between about 2 hours to about 48 hours , preferably about 16 hours . when r 5 is a nitrogen containing heterocycloalkyl group , each nitrogen must be protected by a protecting group , such a benzyl . removal of the r 5 protecting group is carried out under conditions appropriate for that particular protecting group in use which will not affect the r protecting group on the pyrrolo [ 2 , 3 - d ] pyrimidine ring . removal of the r 5 protecting group , when benzyl , is carried out in an alcohol solvent , such as ethanol , in the present of hydrogen and a catalyst , such as palladium hydroxide on carbon . the r 5 nitrogen containing hetrocycloalkyl group so formed may be further reacted with a variety of different electrophiles of formula ii . for urea formation , electrophiles of formula ii such as isocyanates , carbamates and carbamoyl chlorides are reacted with the r 5 nitrogen of the heteroalkyl group in a solvent , such as acetonitrile or dimethylformamide , in the presence of a base , such as sodium or potassium carbonate , at a temperature between about 20 ° c . to about 100 ° c . for a time period between about 24 hours to about 72 hours . for amide and sulfonamide formation , electrophiles of formula ii , such as acylchlorides and sulfonyl chlorides , are reacted with the r 5 nitrogen of the heteroalkyl group in a solvent such as methylene chloride in the presence of a base such as pyridine at ambient temperatures for a time period between about 12 hours to about 24 hours . amide formation may also be carried out by reacting a carboxylic acid with the heteroalkyl group in the presence of a carbodiimide such as 1 -( 3 - dimethylaminopropyl )- 3 - ethylcarbodiimide in a solvent such as methylene chloride at ambient temperatures for 12 - 24 hours . for alkyl formation , electrophiles of formula ii , such as α , β - unsaturated amides , acids , nitriles , esters , and α - halo amides , are reacted with the r 5 nitrogen of the heteroalkyl group in a solvent such as methanol at ambient temperatures for a time period between about 12 hours to about 18 hours . alkyl formation may also be carried out by reacting aldehydes with the heteroalkyl group in the presence of a reducing agent , such as sodium cyanoborohydride , in a solvent , such as methanol , at ambient temperature for a time period between about 12 hours to about 18 hours . in reaction 3 of scheme 1 , removal of the protecting group from the compound of formula xv , wherein r is benzenesulfonyl , to give the corresponding compound of formula i , is carried out by treating xv with an alkali base , such as sodium hydroxide or potassium hydroxide , in an alcohol solvent , such as methanol or ethanol , or mixed solvents , such as alcohol / tetrahydrofuran or alcohol / water . the reaction is carried out at room temperature for a time period between about 15 minutes to about 1 hour , preferably 30 minutes . removal of the protecting group from the compound of formula xv , wherein r is benzyl , is conducted by treating xv with sodium in ammonia at a temperature of about − 78 ° c . for a time period between about 15 minutes to about 1 hour . in reaction 1 of scheme 2 , the 4 - chloropyrrolo [ 2 , 3 - d ] pyrimidine compound of formula xx is converted to the corresponding 4 - aminopyrrolo [ 2 , 3 - d ] pyrimidine compound of formula xxiv , according to the procedure described above in reaction 2 of scheme 1 . in reaction 2 of scheme 2 , the 4 - amino - 5 - halopyrrolo [ 2 , 3 - d ] pyrimidine compound of formula xxiv , wherein r is benzenesulfonate and z is bromine or iodine , is converted to the corresponding compound of formula xxiii by reacting xxiv with ( a ) arylboronic acid , when r 2 is aryl , in an aprotic solvent , such tetrahydrofuran or dioxane , in the presence of a catalytic quantity of palladium ( 0 ) at a temperature between about 50 ° c . to about 100 ° c ., preferably about 70 ° c ., for a time period between about 2 hours to about 48 hours , preferably about 12 hours ; ( b ) alkynes , when r 2 is alkynyl , in the presence of a catalytic quantity of copper ( i ) iodide and palladium ( 0 ), and a polar solvent , such as dimethylformamide , at room temperature , for a time period between about 1 hour to about 5 hours , preferably about 3 hours ; and ( c ) alkenes or styrenes , when r 2 is vinyl or styrenyl , in the presence of a catalytic quantity of palladium in dimethylformamide , dioxane or tetrahydrofuran , at a temperature between about 80 ° c . to about 100 ° c ., preferably about 100 ° c ., for a time period between about 2 hours to about 48 hours , preferably about 48 hours . in reaction 3 of scheme 2 , the compound of formula xxiii is converted to the corresponding compound of formula xv , according to the procedure described above in reaction 3 of preparation a . in reaction 1 of scheme 3 , the compound of formula xvii is converted to the corresponding compound of formula i , according to the procedure described above in reaction 2 of scheme 1 . the compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids . although such salts must be pharmaceutically acceptable for administration to animals , it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt . the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent , such as methanol or ethanol . upon careful evaporation of the solvent , the desired solid salt is readily obtained . the desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid . those compounds of the present invention that are acidic in nature , are capable of forming base salts with various pharmacologically acceptable cations . examples of such salts include the alkali metal or alkaline - earth metal salts and particularly , the sodium and potassium salts . these salts are all prepared by conventional techniques . the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non - toxic base salts with the acidic compounds of the present invention . such non - toxic base salts include those derived from such pharmacologically acceptable cations as sodium , potassium calcium and magnesium , etc . these salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations , and then evaporating the resulting solution to dryness , preferably under reduced pressure . alternatively , they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together , and then evaporating the resulting solution to dryness in the same manner as before . in either case , stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product . the compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers . thus , the active compounds of the invention may be formulated for oral , buccal , intranasal , parenteral ( e . g ., intravenous , intramuscular or subcutaneous ) or rectal administration or in a form suitable for administration by inhalation or insufflation . the active compounds of the invention may also be formulated for sustained delivery . for oral administration , the pharmaceutical compositions may take the form of , for example , tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents ( e . g ., pregelatinized maize starch , polyvinylpyrrolidone or hydroxypropyl methylcellulose ); fillers ( e . g ., lactose , microcrystalline cellulose or calcium phosphate ); lubricants ( e . g ., magnesium stearate , talc or silica ); disintegrants ( e . g ., potato starch or sodium starch glycolate ); or wetting agents ( e . g ., sodium lauryl sulphate ). the tablets may be coated by methods well known in the art . liquid preparations for oral administration may take the form of , for example , solutions , syrups or suspensions , or they may be presented as a dry product for constitution with water or other suitable vehicle before use . such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents ( e . g ., sorbitol syrup , methyl cellulose or hydrogenated edible fats ); emulsifying agents ( e . g ., lecithin or acacia ); non - aqueous vehicles ( e . g ., almond oil , oily esters or ethyl alcohol ); and preservatives ( e . g ., methyl or propyl p - hydroxybenzoates or sorbic acid ). for buccal administration , the composition may take the form of tablets or lozenges formulated in conventional manner . the active compounds of the invention may be formulated for parenteral administration by injection , including using conventional catheterization techniques or infusion . formulations for injection may be presented in unit dosage form , e . g ., in ampules or in multi - dose containers , with an added preservative . the compositions may take such forms as suspensions , solutions or emulsions in oily or aqueous vehicles , and may contain formulating agents such as suspending , stabilizing and / or dispersing agents . alternatively , the active ingredient may be in powder form for reconstitution with a suitable vehicle , e . g ., sterile pyrogen - free water , before use . the active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas , e . g ., containing conventional suppository bases such as cocoa butter or other glycerides . for intranasal administration or administration by inhalation , the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer , with the use of a suitable propellant , e . g ., dichlorodifluoromethane , trichlorofluoromethane , dichlorotetrafluoroethane , carbon dioxide or other suitable gas . in the case of a pressurized aerosol , the dosage unit may be determined by providing a valve to deliver a metered amount . the pressurized container or nebulizer may contain a solution or suspension of the active compound . capsules and cartridges ( made , for example , from gelatin ) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch . a proposed dose of the active compounds of the invention for oral , parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above ( e . g ., rheumatoid arthritis ) is 0 . 1 to 1000 mg of the active ingredient per unit dose which could be administered , for example , 1 to 4 times per day . aerosol formulations for treatment of the conditions referred to above ( e . g ., asthma ) in the average adult human are preferably arranged so that each metered dose or “ puff ” of aerosol contains 20 μg to 1000 μg of the compound of the invention . the overall daily dose with an aerosol will be within the range 0 . 1 mg to 1000 mg . administration may be several times daily , for example 2 , 3 , 4 or 8 times , giving for example , 1 , 2 or 3 doses each time . a compound of formula ( i ) administered in a pharmaceutically acceptable form either alone or in combination with one or more additional agents which modulate a mammlian immune system or with antiinflammatory agents , agents which may include but are not limited to cyclosporin a ( e . g . sandimmune ® or neoral ®, rapamycin , fk - 506 ( tacrolimus ), leflunomide , deoxyspergualin , mycophenolate ( e . g . cellcept ®, azathioprine ( e . g . imuran ®), daclizumab ( e . g . zenapax ®), okt3 ( e . g . orthocolone ®), atgam , aspirin , acctaminophen , ibuprofen , naproxen , piroxicam , and antiinflammatory steroids ( e . g . prednisolone or dexamethasone ); and such agents may be administered as part of the same or separate dosage forms , via the same or different routes of administration , and on the same or different administration schedules according to standard pharmaceutical practice . fk506 ( tacrolimus ) is given orally at 0 . 10 - 0 . 15 mg / kg body weight , every 12 hours , within first 48 hours postoperative . does is monitored by serum tacrolimus trough levels . cyclosporin a ( sandimmune oral or intravenous formulation , or neoral ®, oral solution or capsules ) is given orally at 5 mg / kg body weight , every 12 hours within 48 hours postoperative . dose is monitored by blood cyclosporin a trough levels . the active agents can be formulated for sustained delivery according to methods well known to those of ordinary skill in the art . examples of such formulations can be found in u . s . pat . nos . 3 , 538 , 214 , 4 , 060 , 598 , 4 , 173 , 626 , 3 , 119 , 742 , and 3 , 492 , 397 . the ability of the compounds of formula i or their pharmaceutically acceptable salts to inhibit janus kinase 3 and , consequently , demonstrate their effectiveness for treating disorders or conditions characterized by janus kinase 3 is shown by the following in vitro assay tests . the jak3 kinase assay utilizes a protein expressed in baculovirus - infected sf9 cells ( a fusion protein of gst and the catalytic domain of human jak3 ) purified by affinity chromatography on glutathione - sepaharose . the substrate for the reaction is poly - glutamic acid - tyrosine ( pgt ( 4 : 1 ), sigma catalog # p0275 ), coated onto nunc maxi sorp plates at 100 μg / ml overnight at 37 ° c . the morning after coating , the plates are washed three times and jak3 is added to the wells containing 100 μl of kinase buffer ( 50 mm hepes , ph 7 . 3 , 125 mm nacl , 24 mm mgcl2 )+ 0 . 2 um atp + 1 mm na orthovanadate .) the reaction proceeds for 30 minutes at room temperature and the plates is washed three more times . the level of phosphorylated tyrosine in a given well is quantitated by standard elisa assay utilizing an anti - phosphotyrosine antibody ( icn py20 , cat . # 69 - 151 - 1 ). this screen measures the inhibitory effect of compounds on il - 2 dependent t - cell blast proliferation in vitro . since signaling through the il - 2 receptor requires jak - 3 , cell active inhibitors of jak - 3 should inhibit il - 2 dependent t - cell blast proliferation . the cells for this assay are isolated from fresh human blood . after separation of the mononuclear cells using accuspin system - histopaque - 1077 ( sigma # a7054 ), primary human t - cells are isolated by negative selection using lympho - kwik t ( one lambda , inc ., cat # lk - 50t ). t - cells are cultured at 1 - 2 × 10 6 / ml in media ( rpmi + 10 % heat - inactivated fetal calf serum ( hyclone cat # a - 1111 - l ) + 1 % penicillin / streptomycin ( gibco )) and induce to proliferate by the addition of 10 ug / ml pha ( murex diagnostics , cat # ha 16 ). after 3 days at 37 ° c . in 5 % co 2 , cells are washed 3 times in media , resuspended to a density of 1 - 2 × 10 6 cells / ml in media plus 100 units / ml of human recombinant il - 2 ( r & amp ; d systems , cat # 202 - il ). after 1 week the cells are il - 2 dependent and can be maintained for up to 3 weeks by feeding twice weekly with equal volumes of media + 100 units / ml of il - 2 . to assay for a test compounds ability to inhibit il - 2 dependent t - cell proliferation , il - 2 dependent cells are washed 3 times , resuspended in media and then plated ( 50 , 000 cells / well / 0 . 1 ml ) in a flat - bottom 96 - well microtiter plate ( falcon # 353075 ). from a 10 mm stock of test compound in dmso , serial 2 - fold dilutions of compound are added in triplicate wells starting at 10 um . after one hour , 10 units / ml of il - 2 is added to each test well . plates are then incubated at 37 ° c ., 5 % co 2 for 72 hours . plates are then pulsed with 3 h - thymidine ( 0 . 5 uci / well ) ( nen cat # net - 027a ), and incubated an additional 18 hours . culture plates are then harvested with a 96 - well plate harvester and the amount of 3 h - thymidine incorporated into proliferating cells is determined by counting on a packard top count scintillation counter . data is analyzed by plotting the % inhibition of proliferation verses the concentration of test compound . an ic 50 value ( um ) is determined from this plot . the following examples illustrate the preparation of the compounds of the present invention but it is not limited to the details thereof . melting points are uncorrected . nmr data are reported in parts per million ( δ ) and are referenced to the deuterium lock signal from the sample solvent ( deuteriochloroform unless otherwise specified ). commercial reagents were utilized without further purification . thf refers to tetrahydrofuran . dmf refers to n , n - dimethylformamide . low resolution mass spectra ( lrms ) were recorded on either a hewlett packard 5989 ®, utilizing chemical ionization ( ammonium ), or a fisons ( or micro mass ) atmospheric pressure chemical ionization ( apci ) platform which uses a 50 / 50 mixture of acetonitrile / water with 0 . 1 % formic acid as the ionizing agent . room or ambient temperature refers to 20 - 25 ° c . to a stirred solution of 1 - benzyl - 4 - methyl - piperidin - 3 - one ( 2 . 3 grams , 11 . 5 mmol ), prepared by the methods of lorio , m . a . and damia , g ., tetrahedron , 26 , 5519 ( 1970 ) and grieco et al ., journal of the american chemical society , 107 , 1768 ( 1985 ), ( modified using 5 % methanol as a co - solvent ), both references are incorporated by reference in their entirety , dissolved in 23 ml of 2 m methylamine in tetrahydrofuran was added 1 . 4 ml ( 23 mmol ) of acetic acid and the resulting mixture stirred in a sealed tube for 16 hours at room temperature . triacetoxy sodium borohydride ( 4 . 9 grams , 23 mmol ) was added and the new mixture stirred at room temperature in a sealed tube for 24 h , at which time , the reaction was quenched upon addition of 1 n sodium hydroxide ( 50 ml ). the reaction mixture was then extracted 3 × 80 ml with ether , the combined ether layers dried over sodium sulfate ( na 2 so 4 ) and concentrated to dryness in vacuo affording 1 . 7 grams ( 69 %) of the title compound as a white solid . lrms : 219 . 1 ( m + 1 ). a solution of 4 - chloropyrrolo [ 2 , 3 - d ] pyrimidine ( 2 . 4 grams , 15 . 9 mmol ), prepared by the method of davoll , j . am . chem . soc ., 82 , 131 ( 1960 ), which is incorporated by reference in its entirety , and the product from method a ( 1 . 7 grams , 7 . 95 mmol ) dissolved in 2 equivalents of triethylamine was heated in a sealed tube at 100 ° c . for 3 days . following cooling to room temperature and concentration under reduced pressure , the residue was purified by flash chromatography ( silica ; 3 % methanol in dichloromethane ) affording 1 . 3 grams ( 50 %) of the title compound as a colorless oil . lrms : 336 . 1 ( m + 1 ). to the product from method b ( 0 . 7 grams , 2 . 19 mmol ) dissolved in 15 ml of ethanol was added 1 . 5 ml of 2 n hydrochloric acid and the reaction mixture degassed by nitrogen purge . to the reaction mixture was then added 0 . 5 grams of 20 % palladium hydroxide on carbon ( 50 % water ) ( aldrich ) and the resulting mixture shaken ( parr - shaker ) under a 50 psi atmosphere of hydrogen at room temperature for 2 days . the celite filtered reaction mixture was concentrated to dryness in vacuo and the residue purified by flash chromatography ( silica ; 5 % methanol in dichoromethane ) affording 0 . 48 grams ( 90 %) of the title compound . lrms : 246 . 1 ( m + 1 ). to a stirred solution of the product from method c ( 0 . 03 grams , 0 . 114 mmol ) dissolved in 5 ml of 10 : 1 dichloromethane / pyridine was added ( 0 . 018 grams , 0 . 228 mmol ) of acetylchloride and the resulting mixture stirred at room temperature for 18 hours . the reaction mixture was then partitioned between dichloromethane and saturated sodium bicarbonate ( nahco 3 ). the organic layer was washed again with saturated nahco 3 , dried over sodium sulfate and concentrated to dryness in vacuo . the residue was purified by preparative thin layer chromatography ( ptlc ) ( silica ; 4 % methanol in dichloromethane ) affording 0 . 005 mg ( 15 %) of the title compound as a colorless oil . lrms : 288 . 1 ( m + 1 ). the title compounds for examples 2 - 26 were prepared by a method analogous to that described in example 1 .
a compound of the formula wherein r 1 , r 2 and r 3 are as defined above , which are inhibitors of the enzyme protein kinases such as janus kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants , xeno transplation , lupus , multiple sclerosis , rheumatoid arthritis , psoriasis , type i diabetes and complications from diabetes , cancer , asthma , atopic dermatitis , autoimmune thyroid disorders , ulcerative colitis , crohn &# 39 ; s disease , alzheimer &# 39 ; s disease , leukemia and other autoimmune diseases .